cobas® 4800 BRAF V600 Mutation Test 

 
Registration Status

CE-IVD
US-IVD
A companion diagnostic for vemurafenib
The cobas® 4800 BRAF V600 Mutation Test detects the BRAF V600E mutation in formalin-fixed, paraffin-embedded (FFPET) human melanoma tissue. It is designed to help select patients for treatment with vemurafenib, an oral medicine designed to treat patients whose melanoma tumors harbor a mutated form of the BRAF gene.
Features and Benefits
  • The cobas® BRAF Mutation Test was used in pivotal clinical trials for vemurafenib, to select patients whose tumors harbor the V600E mutation in the BRAF gene.
  • In pre-clinical and clinical investigations, the cobas® BRAF Mutation Test had 97.3% positive agreement in detecting the BRAF V600E (1799 T>A) mutation, which represents >~85% of all BRAF mutations reported in the COSMIC database.
  • The cobas® BRAF Mutation Test is more sensitive in the detection of V600E mutations than Sanger sequencing.*
  • In formalin-fixed, paraffin-embedded tissue (FFPET), the cobas® BRAF Mutation Test can detect V600E mutations at >5% mutation level.*
  • The test may also detect other V600 mutations such as V600D and V600K.*
  • The cobas® BRAF Mutation Test has a low failure rate and is highly reproducible across operators, reagent lots and testing days.*
  • The cobas® BRAF Mutation Test can be performed in <8 hours from receipt of specimen.
  • Liquid, ready-to-use reagents are provided in the test kit to increase laboratory efficiency.
  • The test kits have >12 months shelf life from date of manufacture and upon opening each reagent maintains open-vial stability for up to 90 days.
Intended Use
 
(FDA-IVD, 07/2011, Doc Rev. 1.0)
The cobas® 4800 BRAF V600 Mutation Test is an in vitro diagnostic device intended for the qualitative detection of the BRAF V600E mutation in DNA extracted from formalin-fixed, paraffin-embedded human melanoma tissue. The cobas® 4800 BRAF V600 Mutation Test is a real-time PCR test on the cobas® 4800 System, v2.0, and is intended to be used as an aid in selecting melanoma patients whose tumors carry the BRAF V600E mutation for treatment with vemurafenib.
 
(CE-IVD, 02/2011, Rev. 1.0)
The primary use of the cobas® 4800 BRAF V600 Mutation Test is the detection of the BRAF V600 mutations in DNA extracted from formalin-fixed, paraffin-embedded human melanoma tissue.
*cobas® 4800 BRAF V600 Mutation Test FDA-IVD package insert
More Information
 
For regulatory reasons we are not able to provide further details on our products on this website, but more information may be available from our regional sales representatives.
 
 
Contact

Contact your local sales representative for detailed information, questions and ordering.

 

Browse Our Products

 

 Related Instruments

 Related Kits